文献速递肺栓塞与肺血管病间质性肺疾病

利奥西呱治疗特发性间质性肺炎相关肺动脉高压(RISE-IIP):随机、安慰剂对照2b期研究

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
PubMed 文献 · Lancet Respir Med · 2019-08-12

因利奥西呱组严重不良事件和死亡增加且无疗效信号,研究提前终止;26周时6分钟步行距离较安慰剂无改善(最小二乘均值差21 m,95%CI -9至52)。结论:利奥西呱不应用于PH-IIP患者。

要点

  • 利奥西呱组严重不良事件27/73(37%) vs 安慰剂17/74(23%),研究提前终止。
  • 主研究死亡11例(利奥西呱8例、安慰剂3例),扩展期死亡9例。
  • 26周6分钟步行距离无改善(最小二乘均值差21 m,95%CI -9至52)。

核心结论

  • 在PH-IIP患者中,利奥西呱与严重不良事件和死亡增加相关,风险-获益比不利。
  • 利奥西呱不应用于特发性间质性肺炎相关肺动脉高压患者。

研究设计与样本

  • RISE-IIP为双盲、随机、安慰剂对照2b期研究,在19国65个肺动脉高压和间质性肺病中心开展。
  • 纳入229例,排除82例后147例随机分配(利奥西呱73例、安慰剂74例),治疗26周。
  • 主要终点为意向治疗人群6分钟步行距离变化;预设安全性变量包括不良事件、严重不良事件、实验室参数及特殊关注不良事件(咯血和症状性低血压)。

主要发现

  • 研究因数据监测委员会要求提前终止(中位治疗时长157天,范围6–203)。
  • 主研究严重不良事件:利奥西呱组27/73(37%) vs 安慰剂组17/74(23%)。
  • 主研究死亡11例(利奥西呱8例、安慰剂3例);扩展期死亡9例(利奥西呱组1例、原安慰剂组8例,均接受利奥西呱)。
  • 主研究最常见不良事件为外周水肿(利奥西呱16/73[22%] vs 安慰剂7/74[9%])和腹泻(11/73[15%] vs 7/74[9%])。
  • 26周6分钟步行距离较安慰剂无改善(最小二乘均值差21 m;95%CI -9至52)。

关键数值与推荐

  • 纳入标准:年龄18–80岁、按ATS/ERS/JRS/ALAT指南诊断特发性间质性肺炎、FVC≥45%、6MWD 150–450 m、WHO功能分级II–IV、右心导管证实毛细血管前肺动脉高压、收缩压≥95 mm Hg且无低血压症状体征。
  • 主要终点:意向治疗人群26周6分钟步行距离变化。

临床怎么用

  • 对特发性间质性肺炎相关肺动脉高压患者,不应使用利奥西呱。
  • 临床需关注该类患者使用利奥西呱时严重不良事件和死亡风险增加。

局限性

  • 研究因安全性问题提前终止,中位治疗时长仅157天(范围6–203),疗效与安全性评估受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic interstitial pneumonias are often complicated by pulmonary hypertension, increasing morbidity and mortality. There are no approved treatments for pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP). We aimed to evaluate the efficacy and safety of riociguat in patients with PH-IIP. METHODS: RISE-IIP was a double-blind, randomised, placebo-controlled study done at 65 pulmonary hypertension and interstitial lung disease centres in 19 countries to evaluate the efficacy and safety of riociguat in patients with PH-IIP. Eligible patients were adults (aged 18-80 years) diagnosed with idiopathic interstitial pneumonia (as per American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines), forced vital capacity (FVC) of at least 45%, 6MWD of 150-450 m, WHO functional classes II-IV, precapillary pulmonary hypertension confirmed by right heart catheterisation, systolic blood pressure of at least 95 mm Hg, and no signs or symptoms of hypotension. Patients were randomly allocated (1:1) using an interactive voice and web response system to riociguat (0·5-2·5 mg three times daily) or placebo for 26 weeks (main study), after which they could enter an open-label extension in which all patients received riociguat. The primary endpoint was change in 6-min walking distance (6MWD) in the intention-to-treat population. Prespecified safety variables included adverse events and serious adverse events, laboratory parameters, and adverse events of special interest (haemoptysis and symptomatic hypotension), assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT02138825. FINDINGS: Between June 4, 2014, and May 5, 2016, we enrolled 229 participants. After the exclusion of 82 participants, 147 were randomly allocated to treatment (73 to riociguat, 74 to placebo). The study was terminated early (median treatment duration 157 days [range 6-203]) at the request of the data monitoring committee owing to increased serious adverse events (main study: 27 [37%] of 73 participants in the riociguat group vs 17 [23%] of 74 in the placebo group) and mortality in patients receiving riociguat, and the absence of efficacy signals in the riociguat group. 11 patients died in the main study (eight in the riociguat group, three in the placebo group), and nine died in the extension phase (one in the riociguat group, eight in the former placebo group; all received riociguat). In the main study, the most common adverse events were peripheral oedema (16 [22%] of 73 in the riociguat group vs seven [9%] of 74 in the placebo group) and diarrhoea (11 [15%] vs seven [9%]). The most common serious adverse events were worsening of interstitial lung disease (main study: six [8%] of 73 in the riociguat group vs five [7%] of 74 in the placebo group) and pneumonia (four [5%] vs one [1%]). Riociguat did not improve 6MWD versus placebo at 26 weeks (least-squares mean difference 21 m; 95% CI -9 to 52). INTERPRETATION: In patients with PH-IIP, riociguat was associated with increased serious adverse events and mortality, and an unfavourable risk-benefit profile. Riociguat should not be used in patients with PH-IIP. FUNDING: Bayer AG and Merck & Co.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med. 2019. PMID: 31416769. doi:10.1016/S2213-2600(19)30250-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。